Neffy—the adrenaline nasal spray used for the treatment of anaphylaxis—was approved in the UK last summer and has been out in the market privately since October 2025.
I haven’t yet seen anyone I nurse using it, but I’m really looking forward to its rollout in the future.
What attracts me to Neffy is its longer shelf life compared to standard EpiPens.
It’s also much smaller and easier to carry, which is fantastic!
I've noticed that some people are less likely to carry the two EpiPens they're advised to have on hand because they can be bulky, making it harder to keep them easily accessible.
Having trained many individuals to use EpiPens, I’ve heard that Neffy will be easier to teach and use, reducing the chances of error. It also eliminates the needle phobia that can prevent people from using their EpiPens effectively.
Exciting times ahead for allergy management! www.narf.org.uk/blog/2025/10...
